Hidetoshi Ozawa

Kurume, 8300011, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.

High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.

Journal: International journal of hematology

Published: March 04, 2024

CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.

CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.

Journal: International journal of hematology

Published: February 22, 2024

Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.

Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.

Journal: International journal of hematology

Published: November 06, 2023

Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.

Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.

Journal: Leukemia research

Published: April 13, 2023

IKZF1plus alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial.

IKZF1plus alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial.

Journal: European journal of haematology

Published: August 17, 2022

Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.

Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.

Journal: International journal of hematology

Published: August 03, 2020

Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.

Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: January 08, 2020

CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.

CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.

Journal: International journal of hematology

Published: July 24, 2019

Notch1 expression is regulated at the post-transcriptional level by the 3' untranslated region in hematopoietic stem cell development.

Notch1 expression is regulated at the post-transcriptional level by the 3' untranslated region in hematopoietic stem cell development.

Journal: International journal of hematology

Published: October 05, 2017

Amphiphysin I but not dynamin I nor synaptojanin mRNA expression increased after repeated methamphetamine administration in the rat cerebrum and cerebellum.

Amphiphysin I but not dynamin I nor synaptojanin mRNA expression increased after repeated methamphetamine administration in the rat cerebrum and cerebellum.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: May 23, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026